Immunotherapy for transplantation-associated viral infections

Roddie, Claire; Peggs, Karl S.

doi:10.1172/jci90599

Cited by 57 publications

(51 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of immunotherapeutic approaches using T cell transfer to combat viral reactivation, improve the rates of immune reconstitution, as well as to prevent GVHD or disease relapse after allo-HSCT. There is clear evidence that infections can be treated by the adoptive transfer of T cells specifically targeting viral antigens [184]. Heslop et al [185] showed that adoptively transferred EBV-specific cytotoxic CD4+ and CD8+ T lymphocytes can reconstitute the patient's immune responses against EBV.…”

Section: Treatment Approaches For Improvement Of Allo-hsct Immune Recmentioning

confidence: 99%

Immune Reconstitution Disorders: Spotlight on Interferons

Mohei

Kellampalli

Louis

2019

Int J Biomed Investig

View full text Add to dashboard Cite

Three decades of research in hematopoietic stem cell transplantation and HIV/AIDS fields have shaped a picture of immune restoration disorders. This manuscript overviews the molecular biology of interferon networks, the molecular pathogenesis of immune reconstitution inflammatory syndrome, and post-hematopoietic stem cell transplantation immune restoration disorders (IRD). It also summarizes the effects of thymic involution on T cell diversity, and the results of the assessment of diagnostic biomarkers of IRD, and tested targeted immunomodulatory treatments

show abstract

Section: Treatment Approaches For Improvement Of Allo-hsct Immune Recmentioning

confidence: 99%

Immune Reconstitution Disorders: Spotlight on Interferons

Mohei

Kellampalli

Louis

2019

Int J Biomed Investig

View full text Add to dashboard Cite

show abstract

“…Other approaches used in the prevention and treatment of CMV infections and diseases are the administration of CMV‐specific intravenous immunoglobulins (CMV‐IVIG) or polyvalent IVIG and the use of adoptive immunotherapy with the transfer of ex vivo generated cytomegalovirus‐specific T cells with the aim to increase or restore immunity against CMV . CMV vaccine are in development but no recommendation can currently be made …”

Section: Antiviral Prophylaxis and Therapy Strategymentioning

confidence: 99%

“…Lack of recovery of immune function in the context of reactivation is associated with prolonged CMV viraemia and adverse outcomes. Adoptive transfer of donor‐derived ex vivo generated CMV‐specific T cells has the potential to restore CMV‐specific immunity with the consequence of avoiding or reducing pharmacologic therapies …”

Section: Antiviral Prophylaxis and Therapy Strategymentioning

confidence: 99%

Advances inCMVinfection prevention and treatment after allo‐HSCT

Girmenia

2019

Adv Cell Gene Ther

View full text Add to dashboard Cite

Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Despite this knowledge, a number of CMV-related diagnostic and therapeutic issues remain critical. No uniform guidance exists for the best strategy to monitor and prevent CMV infection and disease. In particular, we lack standard threshold values for assessing the CMV DNAemia in the monitoring of CMV infection; there is no consensus in the adoption of immunoglobulin therapy and adoptive transfer of HSCT donor-derived CMV-specific T cells. Furthermore, antiviral drugs used in the preemptive therapy are characterized by high levels of toxicity. Of interest, recent availability of new drugs will probably modify the antiviral strategy in a large proportion of patients. The uncertainty in the management of CMV infections is further complicated by the continuous evolution in the transplantation strategies and the consequent infectious risk. This paper will focus on challenging issues in the monitoring, prevention, and treatment of CMV infections in allo-HSCT populations. Assessment of pretransplant CMV status, immunological monitoring after transplant, and CMV disease prevention and therapy strategies will be discussed. K E Y W O R D Scytomegalovirus, diagnosis, hematopoietic stem cell transplant, prophylaxis

show abstract

“…Therapy-related complications after allo-HSCT can especially arise from opportunistic and drug-refractory viral infections mediated by Epstein-Barr virus (EBV), cytomegalovirus (CMV), or human adenovirus (HAdV) [45][46][47]. There is clear evidence that infections can be treated by the adoptive transfer of T cells specifically targeting viral antigens, and a number of technologies have been developed [48]. Heslop et al [49] showed back in the 1990s that adoptively transferred EBV-specific cytotoxic CD4+ and CD8+ T lymphocytes (CTL) can reconstitute the patient's immune responses against EBV and proved long-term persistence of the transferred CTL.…”

Section: Specific Adoptive T-cell Transfer Targeting Viral and Fungalmentioning

confidence: 99%

Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation

Audehm

Krackhardt²

2017

Oncol Res Treat

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a treatment option for a diversity of advanced hematopoietic malignancies providing hope for long-term responses especially due to immunogenic effects associated with the treatment modality. Despite respectable progress in the field, relapses and/or opportunistic infections are major reasons for the high treatment-related mortality. However, a number of novel immunotherapeutic approaches using defined cell populations have been developed to directly target residual malignant cells as well as defined infectious diseases. We here provide an overview of current adoptive cellular immunotherapies in the context of allo-HSCT and close with an outlook on new directions within the field.

show abstract

Immunotherapy for transplantation-associated viral infections

Cited by 57 publications

References 94 publications

Immune Reconstitution Disorders: Spotlight on Interferons

Immune Reconstitution Disorders: Spotlight on Interferons

Advances inCMVinfection prevention and treatment after allo‐HSCT

Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation

Contact Info

Product

Resources

About